This bacterial suspension (2 ml) was added to an equal volume of xylene and mixed for 2 min by vortexing. The OD600 selleckchem was measured. Cell surface hydrophobicity (H) was calculated as follows: [(1-ODaqueous phase)/ODinitial] × 100 [39]. Acknowledgements We thank the PAPPSO (Plateforme d’Analyse Protéomique de Paris Sud Ouest) at the INRA Center at Jouy en Josas for performing the MALDI-TOF/MS experiments. Electronic supplementary material Additional file 1: Table S1- Identification of selected protein spots that showed variation (presence/absence) among the B. longum NCC2705, BS49, BS89 and BS64 strains. Additional file 1 contains Table S1 where are presented spot identification

and characteristics. (XLS 40 KB) Additional file 2: 2D-electrophoretic gel of B. longum NCC2705, BS49, BS89 and BS64 cytosolic proteins. Spots that are present in some strains and absent in others are highlighted. Spot characteristics are listed in Table S1. Additional file 2 contains 2D-electrophoretic gel pictures of B. longum NCC2705, BS49, BS89 and BS64 cytosolic

proteins. (PPT 4 MB) References 1. Bezkorovainy A: Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 2001, 73:399S-405S.PubMed 2. Riedel CU, Foata F, Goldstein DR, Blum S, Eikmanns BJ: Interaction of bifidobacteria with Caco-2 cells-adhesion and impact on expression profiles. Int J Food Microbiol 2006, 110:62–68.PubMedCrossRef 3. Penders J, Stobberingh EE, Brandt PA, Thijs C: The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007, 62:1223–1236.PubMedCrossRef 4. Butel MJ, Suau A, Campeotto PF-6463922 F, Magne F, Aires J, Ferraris L, et al.: Conditions of bifidobacterial colonization in preterm infants: a prospective analysis. J Pediatr Gastroenterol Nutr 2007, 44:577–582.PubMedCrossRef 5. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C: Review article: bifidobacteria as probiotic agents — physiological effects

and clinical benefits. Aliment Pharmacol Ther 2005, 22:495–512.PubMedCrossRef 6. Cross ML: Immune-signalling by orally-delivered probiotic bacteria: effects on common mucosal immunoresponses and protection at distal mucosal sites. Int J Immunopathol Pharmacol 2004, 17:127–134.PubMed 7. Gill HS, Rutherfurd KJ, Cross Glutamate dehydrogenase ML: Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol 2001, 21:264–271.PubMedCrossRef 8. Hirayama K, Rafter J: The role of probiotic bacteria in cancer prevention. Microbes Infect 2000, 2:681–686.PubMedCrossRef 9. Sullivan A, Nord CE: The place of probiotics in human intestinal infections. Int J Antimicrob Agents 2002, 20:313–319.PubMedCrossRef 10. Servin AL: Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004, 28:405–440.PubMedCrossRef 11.